GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Compound class:
Synthetic organic
Comment: This is one of the more potent compounds claimed in patent WO2023245150A1 (Prelude Therapeutics) as lysine acetyltransferase 6A (KAT6A) degraders [1]. It is a PROTAC heterobifunctional molecule with a thalidomide-based cereblon ubiquitin ligase binding moiety linked to a selective KAT6A binding ligand. It promotes formation of a ternary complex that directs KAT6A protein for proteosomal degradation. This mechanism is proposed as an alternative to direct enzyme inhibition.
|
|
Bioactivity Comments |
DC50 for KAT6A is <10 nM, with a Dmax >75% [1]. |
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|